U.S. District Judge Matthew Kacsmaryk is ripping up legal procedure, the better to keep a high-profile abortion case in his hands as the new administration takes over. Last June, the Supreme Court found that the anti-abortion doctors aiming to make abortion drug mifepristone less accessible lacked standing,

Idaho, Kansas and Missouri can pursue legal action to prohibit the Food and Drug Administration from allowing online prescriptions.

Instead of dismissing the case, Judge Matthew Kacsmaryk said three states with no connection to Texas can sue the FDA to try to reimpose restrictions on mifepristone.

The states of Idaho, Kansas and Missouri made the request in U.S. District Court in Amarillo, Texas. The only judge based there is Matthew Kacsmaryk, a nominee of former President Donald Trump who previously ruled in favor of a challenge to the pill’s approval.

A Texas judge has allowed Idaho, Kansas, and Missouri to challenge federal rules on the abortion drug mifepristone. The states want stricter regulations, citing conflict with state abortion laws. The case continues despite a prior Supreme Court decision maintaining access to the drug.

Idaho, Kansas and Missouri can proceed with their push against abortion pill mifepristone, a judge in Texas ruled Thursday. The big picture: The Republican-led states are seeking

Missouri, Kansas and Idaho can press forward with their lawsuit to restrict access to the abortion drug mifepristone, a federal judge ruled Thursday, months after the US Supreme Court had rejected an earlier version of the legal challenge.

In the meantime, abortion opponents have set their sights on shutting down access to abortion pills — mifepristone and misoprostol. The Supreme Court rebuffed one Texas lawsuit targeting ...

After abortion opponents and doctors failed in their case to have the drug restricted — the Supreme Court ruled they lacked standing — Idaho, Kansas, and Missouri stepped in. Meanwhile, other states are making moves to protect reproductive rights.

The three states argue that the FDA's approval of mifepristone for use up to 10 weeks of pregnancy, along with its availability via telemedicine and mail, has contributed to what they view as a public health risk.

A federal judge in Texas is allowing Idaho, Kansas and Missouri to pursue a challenge seeking to restrict access to the abortion pill Mifepristone nationwide.